Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells $46,580.35 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRYGet Free Report) CEO Richard E. Lowenthal sold 5,147 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $9.05, for a total transaction of $46,580.35. Following the completion of the sale, the chief executive officer now directly owns 1,642,193 shares of the company’s stock, valued at $14,861,846.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

ARS Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ SPRY opened at $9.03 on Friday. ARS Pharmaceuticals, Inc. has a fifty-two week low of $2.55 and a fifty-two week high of $11.27. The firm’s 50-day simple moving average is $9.07 and its 200 day simple moving average is $7.02.

ARS Pharmaceuticals (NASDAQ:SPRYGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SPRY. William Blair upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th. Wedbush restated an “outperform” rating and set a $19.00 price objective on shares of ARS Pharmaceuticals in a report on Monday, March 11th. Leerink Partnrs raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th. Finally, SVB Leerink raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $6.00 to $18.00 in a research report on Tuesday, March 5th.

View Our Latest Report on SPRY

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SPRY. Nisa Investment Advisors LLC boosted its holdings in ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock worth $31,000 after acquiring an additional 5,575 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of ARS Pharmaceuticals in the first quarter valued at about $60,000. AJOVista LLC bought a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at about $43,000. Paloma Partners Management Co purchased a new position in ARS Pharmaceuticals during the first quarter worth about $103,000. Finally, China Universal Asset Management Co. Ltd. grew its position in ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock worth $61,000 after purchasing an additional 8,652 shares in the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Featured Stories

Insider Buying and Selling by Quarter for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with's FREE daily email newsletter.